Drug Trial Radar · NCT05873803
The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Sep 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Planned (sponsor's estimate)
Start
Feb 8, 2023
Primary completion
Oct 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Patients will receive GR1802 injection or Placebo every 2 Weeks.
Conditions
- Chronic Rhinosinusitis with Nasal Polyps
Interventions
GR1802 injectionBiological
150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
placeboBiological
0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline at Week 16 in Nasal Congestion/Obstruction Symptom(NCS) Severity ScoreTime frame: at Week 16
- Change From Baseline at Week 16 in Nasal Polyp ScoreTime frame: at Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.